vorasidenib
servier
['vorasidenib']
median independently assessed imaging-based pfs with vorasidenib was 27.7 months (95% ci, 17.0-not estimated) compared with 11.1 months (95% ci, 11.0-13.7) for those treated with placebo (hr, 0.39; 95% ci, 0.27-0.56; p &lt;.001). #asco23 | 
Home of the journal ONCOLOGY®, CancerNetwork® offers different perspectives on oncology/hematology through review articles, news, podcasts, blogs, and more.